Search

Your search keyword '"Schumacher, Claudia"' showing total 11 results
Start Over Author "Schumacher, Claudia" Publisher american society of clinical oncology (asco)
11 results on '"Schumacher, Claudia"'

1. Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

Author

Nitz, Ulrike A., primary, Gluz, Oleg, additional, Kümmel, Sherko, additional, Christgen, Matthias, additional, Braun, Michael, additional, Aktas, Bahriye, additional, Lüdtke-Heckenkamp, Kerstin, additional, Forstbauer, Helmut, additional, Grischke, Eva-Maria, additional, Schumacher, Claudia, additional, Darsow, Maren, additional, Krauss, Katja, additional, Nuding, Benno, additional, Thill, Marc, additional, Potenberg, Jochem, additional, Uleer, Christoph, additional, Warm, Mathias, additional, Fischer, Hans Holger, additional, Malter, Wolfram, additional, Hauptmann, Michael, additional, Kates, Ronald E., additional, Gräser, Monika, additional, Würstlein, Rachel, additional, Shak, Steven, additional, Baehner, Frederick, additional, Kreipe, Hans H., additional, and Harbeck, Nadia, additional

Published
2022
Full Text
View/download PDF

2. Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial.

Author

Gluz, Oleg, primary, Christgen, Matthias, additional, Kuemmel, Sherko, additional, zu Eulenburg, Christine, additional, Braun, Michael, additional, Aktas, Bahriye, additional, Luedtke-Heckenkamp, Kerstin, additional, Forstbauer, Helmut, additional, Grischke, Eva-Maria, additional, Schumacher, Claudia, additional, Krauss, Katja, additional, Thill, Marc, additional, Warm, Mathias, additional, Graeser, Monika Karla, additional, Wuerstlein, Rachel, additional, Kates, Ronald E., additional, Baehner, Frederick L., additional, Nitz, Ulrike, additional, Kreipe, Hans Heinrich, additional, and Harbeck, Nadia, additional

Published
2022
Full Text
View/download PDF

3. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Author

Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kates, Ronald Ernest, Braun, Michael, Kümmel, Sherko, Schumacher, Claudia, Potenberg, Jochem, Kraemer, Stefan, Kleine-Tebbe, Anke, Augustin, Doris, Aktas, Bahriye, Forstbauer, Helmut, Tio, Joke, Von Schumann, Raquel, Liedtke, Cornelia, Grischke, Eva-Maria, Schumacher, Johannes, Wuerstlein, Rachel, Kreipe, Hans Heinrich, and Nitz, Ulrike Anneliese

Subjects
Adult, Cancer Research, Receptor, ErbB-2, Medizin, Breast Neoplasms, Middle Aged, Trastuzumab, Ado-Trastuzumab Emtansine, Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Female, Maytansine, Prospective Studies, 030212 general & internal medicine, Precision Medicine
Abstract

Purpose Human epidermal growth factor receptor 2 (HER2)–positive/hormone receptor (HR)–positive breast cancer is a distinct subgroup associated with lower chemotherapy sensitivity and slightly better outcome than HER2-positive/HR-negative disease. Little is known about the efficacy of the combination of endocrine therapy (ET) with trastuzumab or with the potent antibody-cytotoxic, anti-HER2 compound trastuzumab emtansine (T-DM1) with or without ET for this subgroup. The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer) compares pathologic complete response (pCR) rates of T-DM1 versus trastuzumab with ET in early HER2-positive/HR-positive breast cancer. Patients and Methods In this prospective, neoadjuvant, phase II trial, 375 patients with early breast cancer with HER2-positive and HR-positive status (n = 463 screened) were randomly assigned to 12 weeks of T-DM1 with or without ET or to trastuzumab with ET. The primary end point was pCR (ypT0/is/ypN0). Early response was assessed in 3-week post-therapeutic core biopsies (proliferation decrease ≥ 30% Ki-67 or cellularity response). Secondary end points included safety and predictive impact of early response on pCR. Adjuvant therapy followed national standards. Results Baseline characteristics were well balanced among the arms. More than 90% of patients completed the therapy per protocol. pCR was observed in 41.0% of patients treated with T-DM1, 41.5% of patients treated with T-DM1 and ET, and 15.1% with trastuzumab and ET ( P < .001). Early responders (67% of patients with assessable response) achieved pCR in 35.7% compared with 19.8% in nonresponders (odds ratio, 2.2; 95% CI, 1.24 to 4.19). T-DM1 was associated with a significantly higher prevalence of grade 1 to 2 toxicities, especially thrombocytopenia, nausea, and elevation of liver enzymes. Overall toxicity was low; seventeen therapy-related severe adverse events (T-DM1 arms v trastuzumab plus ET; 5.3% v 3.1%, respectively) were reported. Conclusion The ADAPT HER2-positive/HR-positive trial demonstrates that neoadjuvant T-DM1 (with or without ET) given for only 12 weeks results in a clinically meaningful pCR rate. Thus, a substantial number of patients are spared the adverse effects of systemic chemotherapy.

Published
2017

4. Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

Author

Harbeck, Nadia, primary, Nitz, Ulrike, additional, Christgen, Matthias, additional, Kates, Ronald E., additional, Braun, Michael Wilhelm, additional, Kummel, Sherko, additional, Schumacher, Claudia, additional, Potenberg, Jochem, additional, Malter, Wolfram, additional, Augustin, Doris, additional, Aktas, Bahriye, additional, Forstbauer, Helmut, additional, Tio, Joke, additional, Kleine-Tebbe, Anke, additional, Liedtke, Cornelia, additional, de Haas, Sanne, additional, Deurloo, Regula, additional, Wuerstlein, Rachel, additional, Kreipe, Hans Heinrich, additional, and Gluz, Oleg, additional

Published
2018
Full Text
View/download PDF

6. Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC).

Author

Nitz, Ulrike, primary, Gluz, Oleg, additional, Christgen, Matthias, additional, Grischke, Eva-Maria, additional, Augustin, Doris, additional, Kümmel, Sherko, additional, Braun, Michael Wilhelm, additional, Potenberg, Jochem, additional, Kohls, Andreas, additional, Krauss, Katja, additional, Stefek, Andrea, additional, Schumacher, Claudia, additional, Forstbauer, Helmut, additional, Reimer, Toralf, additional, Fischer, Hans Holger, additional, Liedtke, Cornelia, additional, Wuerstlein, Rachel, additional, Kreipe, Hans Heinrich, additional, and Harbeck, Nadia, additional

Published
2016
Full Text
View/download PDF

7. Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial

Author

Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Braun, Michael, Kummel, Sherko, Potenberg, Jochem, Aktas, Bahriye, Schumacher, Claudia, Forstbauer, Helmut, Augustin, Doris, Kraemer, Stefan, Just, Marianne, Tio, Joke, Kleine-Tebbe, Anke, Liedtke, Cornelia, Kates, Ronald, Hofmann, Daniel, Wuerstlein, Rachel, Kreipe, Hans, Nitz, Ulrike, and West German Study Grp ADAPT HER2

Subjects
Gynecology, Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, Medizin, Endocrine therapy, Targeted therapy, Hormone receptor, Internal medicine, medicine, skin and connective tissue diseases, business, neoplasms, Early breast cancer
Abstract

506 Background: Evidence suggests differential efficacy of standard neoadjuvant chemo- + targeted therapy in HER2+ early breast cancer (eBC) according to hormone-receptor (HR) status. ADAPT HER2+/H...

Published
2015

8. Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.

Author

Gluz, Oleg, primary, Nitz, Ulrike, additional, Kates, Ronald, additional, Hofmann, Daniel, additional, Kümmel, Sherko, additional, Nuding, Benno, additional, Schumacher, Claudia, additional, Aktas, Bahriye, additional, Forstbauer, Helmut, additional, Maass, Nicolai, additional, Braun, Michael Wilhelm, additional, Rezai, Mahdi, additional, Kusche, Manfred, additional, von der Assen, Albert, additional, Shak, Steven, additional, Svedman, Christer, additional, Wuerstlein, Rachel, additional, Harbeck, Nadia, additional, Kreipe, Hans Heinrich, additional, and Christgen, Matthias, additional

Published
2014
Full Text
View/download PDF

9. Impact of prognostic factors on long-term outcomes in metastatic breast cancer (MBC) patients (pts) receiving bevacizumab (B) plus paclitaxel as first-line cytotoxic treatment.

Author

Schneeweiss, Andreas, primary, Schmidt, Marcus, additional, Foerster, Frank Gerhard, additional, Geberth, Matthias, additional, Tesch, Hans, additional, Klare, Peter, additional, Schumacher, Claudia, additional, Hollburg, Wiebke, additional, Soeling, Ulrike, additional, Aktas, Bahriye, additional, Kutscheidt, Andreas, additional, and Kümmel, Sherko, additional

Published
2014
Full Text
View/download PDF

11. Analysis according to prognostic factors in patients (pts) treated with first-line bevacizumab (BEV) combined with paclitaxel (PAC) for HER2-negative metastatic breast cancer (mBC) in a routine oncology practice study.

Author

Schrader, Iris, primary, Foerster, Frank Gerhard, additional, Schneeweiss, Andreas, additional, Geberth, Matthias, additional, Hahn, Lars, additional, Schumacher, Claudia, additional, Hertz-Eichenrode, Martin Michael, additional, Schoenegg, Winfried, additional, Wolfgarten, Matthias Kim, additional, Kutscheidt, Andreas, additional, Schmidt, Marcus, additional, and Aktas, Bahriye, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results